Pathogenetic and biologic significance of TP14ARF alterations in nonsmall cell lung carcinoma

Cancer Genetics and Cytogenetics

Volumn 141, Issue 1, 2003, Pages 5-13

  Park, Myung Jae ^a   Shimizu, Kimihiro ^a   Nakano, Tetsuhiro ^a   Park, Yong Bum ^a,b   Kohno, Takashi ^a   Tani, Masachika ^a   Yokota, Jun ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b National Cancer Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ARF PROTEIN; PROTEIN P16; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER GENETICS; CARCINOGENESIS; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; EXON; FISHER EXACT TEST; GENE DELETION; GENE EXPRESSION; GENE INACTIVATION; HUMAN; HUMAN CELL; LUNG SMALL CELL CANCER; MISSENSE MUTATION; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; POLYMORPHIC LOCUS; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; WILD TYPE;

BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MUTATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53;

MARTES PENNANTI;

EID: 0037311184     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-4608(02)00645-3     Document Type: Article

References (41)

1. Sherr C.J. The Pezcoller lecture. cancer cell cycles revisited Cancer Res. 60:2000;3689-3695.
2. Serrano M., Hannon G.J., Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 366:1993;704-707.
3. Kamb A., Gruis N.A., Weaver-Feldhaus J., Liu Q., Harshman K., Tavtigian S.V., Stockert E., Day R.S., Johnson B.E., Skolnick M.H. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 264:1994;436-440.
4. Nobori T., Miura K., Wu D.J., Lois A., Takabayashi K., Carson D.A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature. 368:1994;753-756.
5. Duro D., Bernard O., Della Valle V., Berger R., Larsen C.J. A new type of p16INK4/MTS1 gene transcript expressed in B-cell malignancies. Oncogene. 11:1995;21-29.
6. Mao L., Merlo A., Bedi G., Shapiro G.I., Edwards C.D., Rollins B.J., Sidransky D. A novel p16INK4A transcript. Cancer Res. 55:1995;2995-2997.
7. Quelle D.E., Zindy F., Ashmun R.A., Sherr C.J. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell. 83:1995;993-1000.
8. Stone S., Jiang P., Dayananth P., Tavtigian S.V., Katcher H., Parry D., Peters G., Kamb A. Complex structure and regulation of the P16 (MTS1) locus. Cancer Res. 55:1995;2988-2994.
9. Serrano M. The INK4a/ARF locus in murine tumorigenesis. Carcinogenesis. 21:2000;865-869.
10. Quelle D.E., Ashmun R.A., Hannon G.J., Rehberger P.A., Trono D., Richter K.H., Walker C., Beach D., Sherr C.J., Serrano M. Cloning and characterization of murine p16INK4a and p15INK4b genes. Oncogene. 11:1995;635-645.
11. Kamijo T., Zindy F., Roussel M.F., Quelle D.E., Downing J.R., Ashmun R.A., Grosveld G., Sherr C.J. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell. 91:1997;649-659.
12. Zhang Y., Xiong Y., Yarbrough W.G. ARF promotes MDM2 degradation and stabilizes p53. ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways Cell. 92:1998;725-734.
13. Stott F.J., Bates S., James M.C., McConnell B.B., Starborg M., Brookes S., Palmero I., Ryan K., Hara E., Vousden K.H., Peters G. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 17:1998;5001-5014.
14. Radfar A., Unnikrishnan I., Lee H.W., DePinho R.A., Rosenberg N. p19(Arf) induces p53-dependent apoptosis during abelson virus-mediated pre-B cell transformation. Proc Natl Acad Sci USA. 95:1998;13194-13199.
15. Herman J.G., Merlo A., Mao L., Lapidus R.G., Issa J.P., Davidson N.E., Sidransky D., Baylin S.B. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 55:1995;4525-4530.
16. Kohno T., Yokota J. How many tumor suppressor genes are involved in human lung carcinogenesis? Carcinogenesis. 20:1999;1403-1410.
17. Hall M., Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res. 68:1996;67-108.
18. Okamoto A., Demetrick D.J., Spillare E.A., Hagiwara K., Hussain S.P., Bennett W.P., Forrester K., Gerwin B., Serrano M., Beach D.H., Harris C.C. Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci USA. 91:1994;11045-11049.
19. Gao N., Hu Y.D., Cao X.Y., Zhou J., Cao S.L. The exogenous wild-type p14ARF gene induces growth arrest and promotes radiosensitivity in human lung cancer cell lines. J Cancer Res Clin Oncol. 127:2001;359-367.
20. Vonlanthen S., Heighway J., Tschan M.P., Borner M.M., Altermatt H.J., Kappeler A., Tobler A., Fey M.F., Thatcher N., Yarbrough W.G., Betticher D.C. Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression. Oncogene. 17:1998;2779-2785.
21. Sanchez-Cespedes M., Reed A.L., Buta M., Wu L., Westra W.H., Herman J.G., Yang S.C., Jen J., Sidransky D. Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer. Oncogene. 18:1999;5843-5849.
22. Fujita T., Kiyama M., Tomizawa Y., Kohno T., Yokota J. Comprehensive analysis of p53 gene mutation characteristics in lung carcinoma with special reference to histological subtypes. Int J Oncol. 15:1999;927-934.
23. Hamada K., Kohno T., Takahashi M., Yamazaki M., Tashiro H., Sugawara C., Ohwada S., Sekido Y., Minna J.D., Yokota J. Two regions of homozygous deletion clusters at chromosome band 9p21 in human lung cancer. Genes Chromosomes Cancer. 27:2000;308-318.
24. Cheng J.Q., Jhanwar S.C., Klein W.M., Bell D.W., Lee W.C., Altomare D.A., Nobori T., Olopade O.I., Buckler A.J., Testa J.R. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res. 54:1994;5547-5551.
25. Xing E.P., Nie Y., Song Y., Yang G.Y., Cai Y.C., Wang L.D., Yang C.S. Mechanisms of inactivation of p14ARF, p15INK4b, and p16INK4a genes in human esophageal squamous cell carcinoma. Clin Cancer Res. 5:1999;2704-2713.
26. Poi M.J., Yen T., Li J., Song H., Lang J.C., Schuller D.E., Pearl D.K., Casto B.C., Tsai M.D., Weghorst C.M. Somatic INK4a-ARF locus mutations. a significant mechanism of gene inactivation in squamous cell carcinomas of the head and neck Mol Carcinog. 30:2001;26-36.
27. Hamada K., Kohno T., Kawanishi M., Ohwada S., Yokota J. Association of CDKN2A(p16)/CDKN2B(p15) alterations and homozygous chromosome arm 9p deletions in human lung carcinoma. Genes Chromosomes Cancer. 22:1998;232-240.
28. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., Baylin S.B. Methylation-specific PCR. a novel PCR assay for methylation status of CpG islands Proc Natl Acad Sci USA. 93:1996;9821-9826.
29. Esteller M., Tortola S., Toyota M., Capella G., Peinado M.A., Baylin S.B., Herman J.G. Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. Cancer Res. 60:2000;129-133.
30. Arap W., Nishikawa R., Furnari F.B., Cavenee W.K., Huang H.J. Replacement of the p16/CDKN2 gene suppresses human glioma cell growth. Cancer Res. 55:1995;1351-1354.
31. Kanda T., Sullivan K.F., Wahl G.M. Histone-GFP fusion protein enables sensitive analysis of chromosome dynamics in living mammalian cells. Curr Biol. 8:1998;377-385.
32. Zakut-Houri R., Bienz-Tadmor B., Givol D., Oren M. Human p53 cellular tumor antigen. cDNA sequence and expression in COS cells EMBO J. 4:1985;1251-1255.
33. Pomerantz J., Schreiber-Agus N., Liegeois N.J., Silverman A., Alland L., Chin L., Potes J., Chen K., Orlow I., Lee H.W., Cordon-Cardo C., DePinho R.A. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell. 92:1998;713-723.
34. Kamijo T., Bodner S., van de Kamp E., Randle D.H., Sherr C.J. Tumor spectrum in ARF-deficient mice. Cancer Res. 59:1999;2217-2222.
35. Yang C.T., You L., Yeh C.C., Chang J.W., Zhang F., McCormick F., Jablons D.M. Adenovirus-mediated p14 (ARF) gene transfer in human mesothelioma cells. J Natl Cancer Inst. 92:2000;636-641.
36. Sekido Y., Fong K.M., Minna J.D. Progress in understanding the molecular pathogenesis of human lung cancer. Biochim Biophys Acta. 1378:1998;F21-F59.
37. Braithwaite K.L., Rabbitts P.H. Multi-step evolution of lung cancer. Semin Cancer Biol. 9:1999;255-265.
38. Wistuba II, Behrens C., Milchgrub S., Bryant D., Hung J., Minna J.D., Gazdar A.F. Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. Oncogene. 18:1999;643-650.
39. Aoyagi Y., Yokose T., Minami Y., Ochiai A., Iijima T., Morishita Y., Oda T., Fukao K., Noguchi M. Accumulation of losses of heterozygosity and multistep carcinogenesis in pulmonary adenocarcinoma. Cancer Res. 61:2001;7950-7954.
40. Cho K.R., Vogelstein B. Genetic alterations in the adenoma-carcinoma sequence. Cancer. 70:1992;1727-1731.
41. Fodde R. The APC gene in colorectal cancer. Eur J Cancer. 38:2002;867-871.